| |
n (% ) |
| Gender |
| |
Female |
2 (6.9) |
| Male |
27 (93.1) |
| Median of age (Q1-Q3) years |
39 (32.5 - 44) |
| Tobacco consumption |
| |
Yes |
12 (41.4) |
| |
No |
17 (58.6) |
| Alcohol consumption |
| |
Yes |
13 (44.8) |
| |
No |
16 (55.2) |
| Transmission category |
| |
MSM |
25 (86.2) |
| Heterosexual |
4 (13.8) |
| HAART |
| |
Yes |
26 (89.6) |
| Type of HAART |
|
| |
NRTIs + NNRTIs |
13 (50.0) |
| NRTIs + PIs |
10 (38.5) |
| Others* |
3 (11.5) |
| Median HAART use (Q1-Q3) months |
16.5 (Q1-Q3: 4.2-50.5) |
| CD4+ cells/mm3 |
| |
≤ 200 |
10 (34.5) |
| 201-499 |
14 (48.3) |
| ≥ 500 |
5 (17.2) |
| Median CD4+ (Q1-Q3) cells/mm3 |
243 (169-455.5) |
| Undetectable viral load |
19 (65.5) |
| Median of viral load (Q1-Q3) log10 |
3.80 (2.76-4.58) |
|
| Q1-Q3=Interquartile Interval; MSM: men who have sex with men. HAART: Highly Active Antiretroviral Therapy; NRTIs: Nucleoside Reverse Transcriptase Inhibitors; NNRTIs: Non-Nucleoside Reverse transcriptase inhibitors; PIs=protease inhibitors. *One patient with NNRTIs+PIs; one patient with NRTIs+NNRTIs+PIs; one patient with four NRTIs. |
| Table 1: Demographic and clinical characteristics in 29 HIV/AIDS infected individuals with HPV-OL. |
